融捷健康(300247) - 2024 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2024 was ¥333,381,515.02, representing a 22.93% increase compared to ¥271,201,740.22 in the same period last year[10]. - The net profit attributable to shareholders of the listed company was ¥28,676,352.56, a 36.30% increase from ¥21,039,872.14 in the previous year[10]. - The net profit after deducting non-recurring gains and losses was ¥28,119,976.96, up 36.58% from ¥20,588,582.07 year-on-year[10]. - The basic earnings per share increased to ¥0.0357, reflecting a growth of 36.26% compared to ¥0.0262 in the previous year[10]. - The company reported a net profit of CNY 3,292.64 million from its overseas subsidiary, Golden Designs INC., representing 24.14% of the company's net assets[28]. - The company reported a total comprehensive income of ¥40,422,796.60 for the first half of 2024, compared to ¥38,365,063.88 in the same period of 2023[82]. - The total profit for the first half of 2024 is CNY 1,880,573.51, compared to CNY 5,314,515.77 in the same period of 2023, indicating a significant decrease[85]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,258,411,430.42, a 3.02% increase from ¥1,221,559,067.16 at the end of the previous year[10]. - The net assets attributable to shareholders of the listed company were ¥1,045,678,103.02, which is a 2.84% increase from ¥1,016,847,716.12 at the end of the previous year[10]. - The total liabilities increased to ¥206,091,684.12, compared to ¥203,461,306.01 in the previous year[81]. - The total equity attributable to owners of the parent company was reported at -¥1,150,076,756.94, slightly improved from -¥1,151,957,330.45 year-over-year[81]. - The total owner's equity at the end of the period is 1,028,773,301.73 CNY, which includes minority interests of 39,817,903.29 CNY[93]. Cash Flow - The net cash flow from operating activities was ¥39,912,213.21, down 51.52% from ¥82,330,869.57 in the previous year[10]. - Cash inflow from operating activities totaled CNY 339,773,848.09, an increase from CNY 293,125,832.97 year-over-year[86]. - The company reported a net cash flow from investment activities of CNY 55,825,175.38, a recovery from a negative cash flow of CNY -20,151,712.95 in the previous year[87]. - The total cash outflow from investment activities was CNY 310,662,663.82, compared to CNY 37,747,122.06 in the previous year[87]. - The company's cash and cash equivalents increased to ¥209,490,134.39 from ¥119,150,981.53 at the beginning of the period, representing a growth of approximately 75.7%[74]. Research and Development - Research and development expenses increased by 35.46% to ¥5,306,502.30, reflecting the company's commitment to product innovation and competitiveness[22]. - The company aims to increase R&D investment and expand its R&D team to address challenges in new product development and innovation pressures[43]. Market Strategy - The company plans to diversify its market strategy to mitigate international market risks, particularly in the U.S. market, where it has significant sales exposure[43]. - The company will enhance market research and analysis to adapt its products and services to meet the increasing demand for functional health products, focusing on smarter and more personalized offerings[43]. Financial Health - The company has no interest-bearing debt, indicating strong financial health and risk resilience[18]. - The company has not made any changes to the fundraising projects during the reporting period[36]. - The company has not engaged in derivative investments or entrusted loans during the reporting period[38][39]. Shareholder Information - The total number of shares outstanding is 804,040,313, with 99.90% being unrestricted shares[63]. - The largest shareholder, Rongjie Investment Holding Group Co., Ltd., holds 14.54% of shares, totaling 116,912,302 shares[67]. - The annual shareholders' meeting had a participation rate of 21.84% and approved several key reports and proposals, including the financial settlement report for 2023[45]. Inventory and Receivables - The inventory balance at the end of the period was ¥160,168,396, compared to ¥143,590,254 at the beginning, indicating an increase of about 11.5%[196]. - The accounts receivable at the end of the period totaled ¥49,386,595.44, up from ¥45,112,154.71 at the beginning, indicating an increase of approximately 9.9%[181]. - The bad debt provision for accounts receivable was ¥3,758,302.56, with a provision rate of 7.61%[182]. Compliance and Governance - The half-year financial report has not been audited, and there are no significant litigation or arbitration matters reported[49]. - The company has confirmed that there are no violations of trust by its controlling shareholders or actual controllers[52]. - The company has not reported any changes in accounting policies or corrections of prior period errors during the current period[90]. Environmental and Social Responsibility - There were no significant environmental penalties or issues reported during the period, and the company has taken measures to reduce carbon emissions[47].